These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 30319122)

  • 1. [Metastatic castration resistant prostate cancer: 2018 perspective.].
    Miñana López B
    Arch Esp Urol; 2018 Sep; 71(8):625-627. PubMed ID: 30319122
    [No Abstract]   [Full Text] [Related]  

  • 2. Advances in systemic therapies for metastatic castration-resistant prostate cancer.
    Pant MK; Abughaban A; Aragon-Ching JB
    Future Oncol; 2014 Nov; 10(14):2213-26. PubMed ID: 25471035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health-related quality of life in men with metastatic castration-resistant prostate cancer.
    Gee A; Challapalli A; Bahl A
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):941-9. PubMed ID: 26512743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic and predictive biomarkers in metastatic castration-resistant prostate cancer.
    Armstrong AJ
    Clin Adv Hematol Oncol; 2017 Mar; 15(3):184-188. PubMed ID: 28398272
    [No Abstract]   [Full Text] [Related]  

  • 5. Update of the Andalusian Association of Urology protocol for the management of metastatic castration-resistant prostate cancer.
    Álvarez-Ossorio JL; Cozar-Olmo JM; Juárez-Soto Á; Medina-López R; Moreno-Jiménez J; Requena-Tapia MJ
    Actas Urol Esp (Engl Ed); 2020 Apr; 44(3):125-130. PubMed ID: 32081443
    [No Abstract]   [Full Text] [Related]  

  • 6. Screening of visceral metastasis in castration-resistant prostate cancer: a cornerstone in personalized patient's care.
    Grobet-Jeandin E; Valerio M
    Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):3-4. PubMed ID: 36203050
    [No Abstract]   [Full Text] [Related]  

  • 7. Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics.
    Mukherji D; Omlin A; Pezaro C; Shamseddine A; de Bono J
    Cancer Metastasis Rev; 2014 Sep; 33(2-3):555-66. PubMed ID: 24452758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is metastatic prostate cancer changing, and how will we know it? It's time for standard nomenclature for nonosseous metastases in clinical trials of patients with metastatic castration resistant prostate cancer.
    Tsao CK; Galsky MD; Oh WK
    Eur Urol; 2014 Aug; 66(2):184-5. PubMed ID: 24433812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current, new and novel therapy for castration-resistant prostate cancer.
    Gaya JM; Ahallal Y; Sanchez-Salas R; Barret E; Rozet F; Galiano M; Macek P; Durand M; Cerruti J; Prapotnich D; Ropert S; Bennamoun M; Cathelineau X
    Expert Rev Anticancer Ther; 2013 Jul; 13(7):819-27. PubMed ID: 23875660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.
    Li J; Armstrong AJ
    Clin Adv Hematol Oncol; 2015 May; 13(5):293-8. PubMed ID: 26352773
    [No Abstract]   [Full Text] [Related]  

  • 11. Continuous, comprehensive and crucial care: The role of the CNS in the metastatic castration-resistant prostate cancer patient pathway.
    Basketter V; Benney M; Causer L; Fleure L; Hames D; Jones S; Patel K; White L
    Br J Nurs; 2018 Feb; 27(Sup4b):S1-S8. PubMed ID: 29461871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Docetaxel still the optimal first choice for symptomatic metastatic castration-resistant prostate cancer.
    Dreicer R
    Clin Adv Hematol Oncol; 2015 May; 13(5):293-5. PubMed ID: 26352772
    [No Abstract]   [Full Text] [Related]  

  • 13. Do the expressions of epithelial-mesenchymal transition proteins, periostin, integrin-α4 and fibronectin correlate with clinico-pathological features and prognosis of metastatic castration-resistant prostate cancer?
    Konac E; Kiliccioglu I; Sogutdelen E; Dikmen AU; Albayrak G; Bilen CY
    Exp Biol Med (Maywood); 2017 Dec; 242(18):1795-1801. PubMed ID: 28836852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer.
    Fendler WP; Reinhardt S; Ilhan H; Delker A; Böning G; Gildehaus FJ; Stief C; Bartenstein P; Gratzke C; Lehner S; Rominger A
    Oncotarget; 2017 Jan; 8(2):3581-3590. PubMed ID: 27683041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current management of advanced and castration resistant prostate cancer.
    Gomella LG; Petrylak DP; Shayegan B
    Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Castration resistant prostate cancer 2015].
    Merseburger AS; Böker A; Kuczyk MA; von Klot CA
    Aktuelle Urol; 2015 Jan; 46(1):59-65. PubMed ID: 25658232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer.
    Sainio M; Visakorpi T; Tolonen T; Ilvesaro J; Bova GS
    Pathol Res Pract; 2018 Jun; 214(6):848-856. PubMed ID: 29728311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug therapies for metastatic castration-resistant prostate cancer.
    El-Bahesh E; Finianos A; Alfaraj A; Aragon-Ching JB
    Future Oncol; 2015; 11(17):2395-403. PubMed ID: 26274603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Castration-naive metastatic prostate cancer: reshaping old paradigms.
    Ratta R; Grassi P; Fucà G; Verzoni E; Procopio G
    Expert Rev Anticancer Ther; 2017 Oct; 17(10):879-881. PubMed ID: 28854837
    [No Abstract]   [Full Text] [Related]  

  • 20. Navigating Treatment of Metastatic Castration- Resistant Prostate Cancer: Nursing Perspectives.
    dela Rama F; Pratz C
    Clin J Oncol Nurs; 2015 Dec; 19(6):723-32. PubMed ID: 26583636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.